250 related articles for article (PubMed ID: 27039170)
1. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
[TBL] [Abstract][Full Text] [Related]
4. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
[TBL] [Abstract][Full Text] [Related]
6. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract][Full Text] [Related]
7. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract][Full Text] [Related]
8. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS
Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
10. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract][Full Text] [Related]
11. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
Wei H; Mao Y; Zhang H; Wu F; Zhang Y
Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.
Miyazaki S; Fujisue K; Yamanaga K; Sueta D; Usuku H; Tabata N; Ishii M; Hanatani S; Hoshiyama T; Kanazawa H; Takashio S; Arima Y; Araki S; Yamamoto E; Matsushita K; Tsujita K
J Atheroscler Thromb; 2024 Apr; 31(4):355-367. PubMed ID: 37793811
[TBL] [Abstract][Full Text] [Related]
13. Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies.
Oya K; Nakamura Y; Shen LT; Ishizuki S; Matsusaka S; Fujisawa Y
J Dermatol; 2024 Jun; 51(6):807-815. PubMed ID: 38433350
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract][Full Text] [Related]
15. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
[TBL] [Abstract][Full Text] [Related]
17. Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma.
Kuang RZ; Wang J; Wang YC; Tang XP
Clinics (Sao Paulo); 2024; 79():100376. PubMed ID: 38733690
[TBL] [Abstract][Full Text] [Related]
18. Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract][Full Text] [Related]
19. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract][Full Text] [Related]
20. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
Chiarucci C; Cannito S; Daffinà MG; Amato G; Giacobini G; Cutaia O; Lofiego MF; Fazio C; Giannarelli D; Danielli R; Di Giacomo AM; Coral S; Calabrò L; Maio M; Covre A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
